OECD, EU. Health at a glance: Europe 2018. 2018.
Doran CM, Kinchin I. A review of the economic impact of mental illness. Aust Health Rev. 2019;43(1):43–8.
Vannieuwenborg L, Buntinx F, De Lepeleire J. Presenting prevalence and management of psychosocial problems in primary care in Flanders. Arch Public Health. 2015;73(1):1–6.
Kessler RC, Amminger GP, Aguilar-Gaxiola S, Alonso J, Lee S, Ustun TB. Age of onset of mental disorders: a review of recent literature. Curr Opin Psychiatry. 2007;20(4):359.
Beecham J. Annual research review: child and adolescent mental health interventions: a review of progress in economic studies across different disorders. J Child Psychol Psychiatry. 2014;55(6):714–32.
Scott S, Knapp M, Henderson J, Maughan B. Financial cost of social exclusion: follow up study of antisocial children into adulthood. BMJ. 2001;323(7306):191.
Currie J, Stabile M. Child mental health and human capital accumulation: the case of ADHD. J Health Econ. 2006;25(6):1094–118.
Hultkrantz L, Karpaty P, Vimefall E. Education-earnings linkage for assessing societal benefits of interventions for children and youth in Sweden. Psychosoc Interv. 2017;26(3):171–9.
Le HH, Hodgkins P, Postma MJ, Kahle J, Sikirica V, Setyawan J, et al. Economic impact of childhood/adolescent ADHD in a European setting: the Netherlands as a reference case. Eur Child Adolesc Psychiatry. 2014;23(7):587–98.
Järbrink K. The economic consequences of autistic spectrum disorder among children in a Swedish municipality. Autism. 2007;11(5):453–63.
Ten JB. arguments for a societal perspective in the economic evaluation of medical innovations. Eur J Health Econ. 2009;10:357–9.
Shearer J, McCrone P, Romeo R. Economic evaluation of mental health interventions: a guide to costing approaches. Pharmacoeconomics. 2016;34(7):651–64.
Mayer S, Paulus AT, Łaszewska A, Simon J, Drost RM, Ruwaard D, et al. Health-related resource-use measurement instruments for intersectoral costs and benefits in the education and criminal justice sectors. Pharmacoeconomics. 2017;35(9):895–908.
Drost R, Paulus A, Ruwaard D, Evers S. Inter-sectoral costs and benefits of mental health prevention: towards a new classification scheme. J Ment Health Policy Econ. 2013;16(4):179–86.
Drost RM, Paulus AT, Ruwaard D, Evers SM. Valuing inter-sectoral costs and benefits of interventions in the healthcare sector: methods for obtaining unit prices. Expert Rev Pharmacoecon Outcomes Res. 2017;17(1):77–84.
Pokhilenko I, Janssen LM, Evers SM, Drost RM, Simon J, König H-H, et al. Exploring the identification, validation, and categorization of costs and benefits of education in mental health: the PECUNIA project. Int J Technol Assess Health Care. 2020;36(4):325–31.
Drost RM, van der Putten IM, Ruwaard D, Evers SM, Paulus AT. Conceptualizations of the societal perspective within economic evaluations: a systematic review. Int J Technol Assess Health Care. 2017;33(2):251–60.
ISPOR. Pharmacoeconomic guidelines around the world. n.d. https://tools.ispor.org/peguidelines/. Accessed 12 Aug 2019.
van Mastrigt GA, Hiligsmann M, Arts JJ, Broos PH, Kleijnen J, Evers SM, et al. How to prepare a systematic review of economic evaluations for informing evidence-based healthcare decisions: a five-step approach (part 1/3). Expert Rev Pharmacoecon Outcomes Res. 2016;16(6):689–704.
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264–9.
Tacconelli E. Systematic reviews: CRD’s guidance for undertaking reviews in health care. Lancet Infect Dis. 2010;10(4):226.
England MJ, Butler AS, Gonzalez ML. Psychosocial interventions for mental and substance use disorders: a framework for establishing evidence-based standards. Washington, DC: National Academy Press; 2015.
Johns B, Baltussen R, Hutubessy R. Programme costs in the economic evaluation of health interventions. Cost Eff Resour Alloc. 2003;1(1):1.
WHO. International classification of diseases for mortality and morbidity statistics (11th Revision). 2018. https://icd.who.int/en. Accessed 7 Aug 2019.
Bramer WM, Giustini D, de Jonge GB, Holland L, Bekhuis T. De-duplication of database search results for systematic reviews in EndNote. J Med Libr Assoc JMLA. 2016;104(3):240.
Wijnen B, Van Mastrigt G, Redekop W, Majoie H, De Kinderen R, Evers S. How to prepare a systematic review of economic evaluations for informing evidence-based healthcare decisions: data extraction, risk of bias, and transferability (part 3/3). Expert Rev Pharmacoecon Outcomes Res. 2016;16(6):723–32.
Inflation tool. 2020. https://www.inflationtool.com/. Accessed 16 Apr 2021.
Converter XC. https://www.xe.com/currencyconverter/. Accessed 16 Apr 2021.
Economic costs associated with mental retardation, cerebral palsy, hearing loss, and vision impairment—United States, 2003. MMWR Morb Mortal Wkly Rep. 2004;53(3):57–9.
Arora S, Goodall S, Viney R, Einfeld S. Societal cost of childhood intellectual disability in Australia. J Intellect Disabil Res. 2020;64(7):524–37. https://doi.org/10.1111/jir.12732.
Barrett B, Byford S, Sharac J, Hudry K, Leadbitter K, Temple K, et al. Service and wider societal costs of very young children with autism in the UK. J Autism Dev Disord. 2011. https://doi.org/10.1007/s10803-011-1393-8.
Beaulieu E, Rajabali F, Zheng A, Pike I. The lifetime costs of pediatric abusive head trauma and a cost-effectiveness analysis of the Period of Purple crying program in British Columbia, Canada. Child Abuse Negl. 2019;97: 104133. https://doi.org/10.1016/j.chiabu.2019.104133.
Bodden DH, Dirksen CD, Bögels SM. Societal burden of clinically anxious youth referred for treatment: a cost-of-illness study. J Abnorm Child Psychol. 2008;36(4):487–97.
Bodden DH, Dirksen CD, Bogels SM, Nauta MH, De Haan E, Ringrose J, et al. Costs and cost-effectiveness of family CBT versus individual CBT in clinically anxious children. Clin Child Psychol Psychiatry. 2008;13(4):543–64. https://doi.org/10.1177/1359104508090602.
Bodden DHM, Stikkelbroek Y, Dirksen CD. Societal burden of adolescent depression, an overview and cost-of-illness study. J Affect Disord. 2018;241:256–62. https://doi.org/10.1016/j.jad.2018.06.015 (Epub 2018 Jul 18).
Buescher AV, Cidav Z, Knapp M, Mandell DS. Costs of autism spectrum disorders in the United Kingdom and the United States. JAMA Pediatr. 2014;168(8):721–8.
Byford S, Cary M, Barrett B, Aldred CR, Charman T, Howlin P, et al. Cost-effectiveness analysis of a communication-focused therapy for pre-school children with autism: results from a randomised controlled trial. BMC Psychiatry. 2015;15:316. https://doi.org/10.1186/s12888-015-0700-x.
Creswell C, Violato M, Cruddace S, Gerry S, Murray L, Shafran R, et al. A randomised controlled trial of treatments of childhood anxiety disorder in the context of maternal anxiety disorder: clinical and cost-effectiveness outcomes. J Child Psychol Psychiatry. 2019. https://doi.org/10.1111/jcpp.13089.
Day C, Briskman J, Crawford MJ, Foote L, Harris L, Boadu J, et al. An intervention for parents with severe personality difficulties whose children have mental health problems: a feasibility RCT. Health Technol Assess. 2020;24(14):1.
Domino ME, Burns BJ, Silva SG, Kratochvil CJ, Vitiello B, Reinecke MA, et al. Cost-effectiveness of treatments for adolescent depression: results from TADS. Am J Psychiatry. 2008;165(5):588–96. https://doi.org/10.1176/appi.ajp.2008.07101610 (Epub 2008 Apr 15).
Drost RM, Paulus AT, Jander AF, Mercken L, de Vries H, Ruwaard D, et al. A web-based computer-tailored alcohol prevention program for adolescents: cost-effectiveness and intersectoral costs and benefits. J Med Int Res. 2016;18(4):e93.
Ericson L, Magnusson L, Hovstadius B. Societal costs of fetal alcohol syndrome in Sweden. Eur J Health Econ. 2017;18(5):575–85. https://doi.org/10.1007/s10198-016-0811-4 (Epub 2016 Jun 8).
Ganz ML. The lifetime distribution of the incremental societal costs of autism. Arch Pediatr Adolesc Med. 2007;161(4):343–9.
Genereaux D, van Karnebeek CD, Birch PH. Costs of caring for children with an intellectual developmental disorder. Disabil Health J. 2015;8(4):646–51.
Greenmyer JR, Klug MG, Kambeitz C, Popova S, Burd L. A multicountry updated assessment of the economic impact of fetal alcohol spectrum disorder: costs for children and adults. J Addict Med. 2018;12(6):466–73.
Hakkaart-van Roijen L, Zwirs BW, Bouwmans C, Tan SS, Schulpen TW, Vlasveld L, et al. Societal costs and quality of life of children suffering from attention deficient hyperactivity disorder (ADHD). Eur Child Adolesc Psychiatry. 2007;16(5):316–26. https://doi.org/10.1007/s00787-007-0603-6 (Epub 2007 May 4).
Järbrink K, Knapp M. The economic impact of autism in Britain. Autism. 2001;5(1):7–22.
Jolstedt M, Wahlund T, Lenhard F, Ljotsson B, Mataix-Cols D, Nord M, et al. Efficacy and cost-effectiveness of therapist-guided internet cognitive behavioural therapy for paediatric anxiety disorders: a single-centre, single-blind, randomised controlled trial. Lancet Child Adolesc Health. 2018;2(11):792–801. https://doi.org/10.1016/s2352-4642(18)30275-x (Epub 2018 Sep 18).
Konnopka A, Konig HH. The health and economic consequences of moderate alcohol consumption in Germany 2002. Value Health. 2009;12(2):253–61. https://doi.org/10.1111/j.1524-4733.2008.00444.x.
Konnopka A, König HH. Direct and indirect costs attributable to alcohol consumption in Germany. Pharmacoeconomics. 2007;25(7):605–18. https://doi.org/10.2165/00019053-200725070-00006.
Kuklinski MR, Oxford ML, Spieker SJ, Lohr MJ, Fleming CB. Benefit-cost analysis of Promoting First Relationships®: implications of victim benefits assumptions for return on investment. Child Abuse Negl. 2020;106: 104515. https://doi.org/10.1016/j.chiabu.2020.104515.
Leijdesdorff SMJ, Huijs CEM, Klaassen RMC, Popma A, van Amelsvoort T, Evers S. Burden of mental health problems: quality of life and cost-of-illness in youth consulting Dutch walk-in youth health centres. J Ment Health. 2020. https://doi.org/10.1080/09638237.2020.1836555.
Lenhard F, Ssegonja R, Andersson E, Feldman I, Ruck C, Mataix-Cols D, et al. Cost-effectiveness of therapist-guided internet-delivered cognitive behaviour therapy for paediatric obsessive-compulsive disorder: results from a randomised controlled trial. BMJ Open. 2017;7(5):e015246. https://doi.org/10.1136/bmjopen-2016-015246.
Oosterhoff M, Over EAB, van Giessen A, Hoogenveen RT, Bosma H, van Schayck OCP, et al. Lifetime cost-effectiveness and equity impacts of the Healthy Primary School of the future initiative. BMC Public Health. 2020;20(1):1887. https://doi.org/10.1186/s12889-020-09744-9.
Pelham WE, Foster EM, Robb JA. The economic impact of attention-deficit/hyperactivity disorder in children and adolescents. J Pediatr Psychol. 2007;32(6):711–27.
Penner M, Rayar M, Bashir N, Roberts SW, Hancock-Howard RL, Coyte PC. Cost-effectiveness analysis comparing pre-diagnosis autism spectrum disorder (ASD)-targeted intervention with Ontario’s Autism Intervention Program. J Autism Dev Disord. 2015;45(9):2833–47. https://doi.org/10.1007/s10803-015-2447-0.
Peterson C, Florence C, Thomas R, Klevens J. Cost-benefit analysis of two child abuse and neglect primary prevention programs for US states. Prev Sci. 2018;19(6):705–15. https://doi.org/10.1007/s11121-017-0819-8.
Piccininni C, Bisnaire L, Penner M. Cost-effectiveness of wait time reduction for intensive behavioral intervention services in Ontario, Canada. JAMA Pediatr. 2017;171(1):23–30. https://doi.org/10.1001/jamapediatrics.2016.2695.
Popova S, Lange S, Burd L, Rehm J. The economic burden of fetal alcohol spectrum disorder in Canada in 2013. Alcohol Alcohol. 2016;51(3):367–75. https://doi.org/10.1093/alcalc/agv117 (Epub 2015 Oct 21).
Quintero J, Ramos-Quiroga JA, Sebastian JS, Montanes F, Fernandez-Jaen A, Martinez-Raga J, et al. Health care and societal costs of the management of children and adolescents with attention-deficit/hyperactivity disorder in Spain: a descriptive analysis. BMC Psychiatry. 2018;18(1):40. https://doi.org/10.1186/s12888-017-1581-y.
Reynolds AJ, Temple JA, White BA, Ou SR, Robertson DL. Age 26 cost-benefit analysis of the child-parent center early education program. Child Dev. 2011;82(1):379–404. https://doi.org/10.1111/j.1467-8624.2010.01563.x.
Roddy A, O’Neill C. The economic costs and its predictors for childhood autism spectrum disorders in Ireland: how is the burden distributed? Autism. 2019;23(5):1106–18. https://doi.org/10.1177/1362361318801586 (Epub 2018 Oct 1).
Sampaio F, Bonnert M, Olen O, Hedman E, Lalouni M, Lenhard F, et al. Cost-effectiveness of internet-delivered cognitive-behavioural therapy for adolescents with irritable bowel syndrome. BMJ Open. 2019;9(1):e023881. https://doi.org/10.1136/bmjopen-2018-023881.
Schawo S, van der Kolk A, Bouwmans C, Annemans L, Postma M, Buitelaar J, et al. Probabilistic Markov model estimating cost effectiveness of methylphenidate osmotic-release oral system versus immediate-release methylphenidate in children and adolescents: which information is needed? Pharmacoeconomics. 2015;33(5):489–509. https://doi.org/10.1007/s40273-015-0259-x.
Simon E, Dirksen C, Bögels S. An explorative cost-effectiveness analysis of school-based screening for child anxiety using a decision analytic model. Eur Child Adolesc Psychiatry. 2013;22(10):619–30. https://doi.org/10.1007/s00787-013-0404-z.
Simon E, Dirksen C, Bogels S, Bodden D. Cost-effectiveness of child-focused and parent-focused interventions in a child anxiety prevention program. J Anxiety Disord. 2012;26(2):287–96. https://doi.org/10.1016/j.janxdis.2011.12.008 (Epub 2011 Dec 27).
Thanh NX, Jonsson E. Costs of fetal alcohol spectrum disorder in Alberta, Canada. Can J Clin Pharmacol. 2009;16(1):e80–90.
Thurston S, Paul L, Loney P, Ye C, Wong M, Browne G. Associations and costs of parental symptoms of psychiatric distress in a multi-diagnosis group of children with special needs. J Intellect Disabil Res. 2011;55(3):263–80. https://doi.org/10.1111/j.1365-2788.2010.01356.x (Epub 2011 Jan 4).
van der Kolk A, Bouwmans CA, Schawo SJ, Buitelaar JK, van Agthoven M, Hakkaart-van Roijen L. Association between societal costs and treatment response in children and adolescents with ADHD and their parents. A cross-sectional study in the Netherlands. Springerplus. 2015;4:224. https://doi.org/10.1186/s40064-015-0978-7 (eCollection 2015).
van der Schans J, Kotsopoulos N, Hoekstra PJ, Hak E, Postma MJ. Cost-effectiveness of extended-release methylphenidate in children and adolescents with attention-deficit/hyperactivity disorder sub-optimally treated with immediate release methylphenidate. PLoS ONE. 2015;10(5):e0127237. https://doi.org/10.1371/journal.pone.0127237 (eCollection 2015).
van Steensel FJ, Dirksen CD, Bögels SM. A cost of illness study of children with high-functioning autism spectrum disorders and comorbid anxiety disorders as compared to clinically anxious and typically developing children. J Autism Dev Disord. 2013;43(12):2878–90.
Vermeulen KM, Jansen DE, Knorth EJ, Buskens E, Reijneveld SA. Cost-effectiveness of multisystemic therapy versus usual treatment for young people with antisocial problems. Crim Behav Ment Health. 2017;27(1):89–102.
Wansink HJ, Drost RM, Paulus AT, Ruwaard D, Hosman CM, Janssens JM, et al. Cost-effectiveness of preventive case management for parents with a mental illness: a randomized controlled trial from three economic perspectives. BMC Health Serv Res. 2016;16(1):228.
Weimer DL, Moberg P, French F, Tanner-Smith EE, Finch AJ. Net benefits of recovery high schools: higher cost but increased sobriety and educational attainment. J Ment Health Policy Econ. 2019;22(3):109–20.
Zhao X, Page TF, Altszuler AR, Pelham WE 3rd, Kipp H, Gnagy EM, et al. Family burden of raising a child with ADHD. J Abnorm Child Psychol. 2019;47(8):1327–38. https://doi.org/10.1007/s10802-019-00518-5.
Hakkaart-van Roijen L, Van der Linden N, Bouwmans C, Kanters T, Tan SS. Kostenhandleiding. Methodologie van kostenonderzoek en referentieprijzen voor economische evaluaties in de gezondheidszorg In opdracht van Zorginstituut Nederland Geactualiseerde versie; 2015.
Lee KM, McCarron CE, Bryan S, Coyle D, Krahn M, McCabe C. Guidelines for the economic evaluation of health technologies: Canada. 4th ed. Ottawa: CADTH; 2017.
HIQA. Guidelines for the Economic Evaluation of Health Technologies in Ireland 2010. Health Information and Quality Authority Publisher; 2010.
NICE. Guide to the methods of technology appraisal. http://www.nice.org.uk/about.nice/howwework/devnicetech/technologyappraisalprocessguides/guidetothemethodsoftechnologyappraisaljsp. 2008.
Salvador-Carulla L, Alvarez-Galvez J, Romero C, Gutiérrez-Colosía MR, Weber G, McDaid D, et al. Evaluation of an integrated system for classification, assessment and comparison of services for long-term care in Europe: the eDESDE-LTC study. BMC Health Serv Res. 2013;13(1):218.
Romero-López-Alberca C, Gutiérrez-Colosía MR, Salinas-Pérez JA, Almeda N, Furst M, Johnson S, et al. Standardised description of health and social care: a systematic review of use of the ESMS/DESDE (European Service Mapping Schedule/Description and Evaluation of Services and DirectoriEs). Eur Psychiatry. 2019;61:97–110.